BC Week In Review | Apr 6, 2018
Clinical News

MediciNova's tipelukast meets in Phase IIa for liver disease

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) said it will stop early a Phase IIa trial of tipelukast (MN-001) to treat non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) after an interim analysis showed that the product...
BC Extra | Apr 2, 2018
Clinical News

Early stop in liver disease trial boosts MediciNova

MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875) shares rose Monday on news it will stop early a Phase IIa trial of tipelukast (MN-001) to treat non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) after an interim analysis...
BC Innovations | Feb 9, 2018
Product R&D

R is for readout

While AstraZeneca plc gets credit for transparency in publishing its metrics on R&D productivity, the data cover well-established targets addressed by conventional modalities. The more telling test for its “5R framework” will be whether it...
BC Innovations | Feb 18, 2016
Distillery Therapeutics

Therapeutics: 5-lipoxygenase (ALOX5; 5-LO)

Cancer INDICATION: Breast cancer Mouse studies suggest inhibiting ALOX5 could help treat metastatic breast cancer. In a mouse model of spontaneous breast cancer, the generic ALOX5 inhibitor zileuton decreased metastasis to the lung compared with...
BC Week In Review | Jan 18, 2016
Clinical News

Tipelukast: Phase IIa started

MediciNova began an open-label Phase IIa trial to evaluate 250 mg oral tipelukast given once daily for 4 weeks and then twice daily for 8 additional weeks in about 20 patients ages 21-65. MediciNova has...
BC Week In Review | Sep 21, 2015
Clinical News

Tipelukast regulatory update

MediciNova said FDA granted Fast Track designation to tipelukast to treat idiopathic pulmonary fibrosis (IPF). MediciNova said the agency approved the protocol for a Phase II trial of the product to treat IPF, but the...
BC Innovations | Aug 27, 2015
Distillery Therapeutics

Therapeutics: Cyclooxygenase-2 (COX-2); 5-lipoxygenase (ALOX5; 5-LO)

Inflammation INDICATION: Inflammation; pain In vitro and mouse studies suggest an inhibitor of COX-2 and ALOX5 could treat pain and inflammation. Chemical synthesis of barbituric acid analogs followed by testing in COX-2 and ALOX5 assays...
BC Week In Review | Jul 27, 2015
Clinical News

NPH29: Clinical trial data

A double-blind clinical trial in 21 patients showed that 1% NPH29 cream significantly improved both visual scoring and instrumentally measured L*a*b*L values from baseline to day 30 vs. both vehicle cream and tranexamic acid (p<0.005...
BC Innovations | Jan 29, 2015
Distillery Therapeutics

Therapeutics: 5-lipoxygenase activating protein (FLAP; ALOX5AP)

Inflammation INDICATION: Inflammation Studies in vitro and in whole blood identified a new FLAP inhibitor that could help treat inflammation. Chemical synthesis and in vitro screening identified a lead compound called AZD6642 that inhibited FLAP...
BC Week In Review | Nov 10, 2014
Clinical News

Tipelukast regulatory update

MediciNova said FDA granted Orphan Drug designation to tipelukast to treat idiopathic pulmonary fibrosis (IPF). MediciNova is finalizing a protocol for a Phase II trial of tipelukast for IPF. Tipelukast is a leukotriene receptor antagonist...
Items per page:
1 - 10 of 167